In the melanoma xenograft model, the eNVs-FAP vaccine effectively inhibited tumor growth by promoting the maturation of DCs, activating specific CTL responses against tumor cells and FAP-positive CAFs, and reducing the proportion of M2-like TAMs, MDSCs, and regulatory T cells (Tregs) to remodel the TME. This evidence concerns the gene FAP and neoplasm.